VDValery Daubie

Valery Daubie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valery Daubie has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rapid phage susceptibility determination using a semi-automated bioluminescent ATP assay

    by Houssein Chalhoub, Valéry Daubie, Hafid Dahma, Bob Blasdel, Isabelle Tytgat, Johan Quintens, Olivier Vandenberg, Marie Hallin

    Antimicrobial resistance is a major threat to human health. Phage therapy is a promising alternative to antibiotics, yet routine diagnostic tools capable of rapidly determining phage susceptibility are lacking. Our goal was to develop a diagnostic tool providing easy-to-interpret in vitro phage activity results within a clinically relevant time frame. We developed a prototype based on bioluminescence emitted by adenosine triphosphate (ATP) release during phage-mediated bacterial lysis. Ten phages were tested against 20 clinical isolates of four species: Pseudomonas aeruginosa , Staphylococcus aureus , Escherichia coli , and Klebsiella pneumoniae . Overall concordance with double agar overlay (DAO) was fair (72%). The prototype showed high sensitivity (94.5%) at detecting weak killers and high specificity (87%) at identifying strong killer phages. Most discordances involved DAO weak killers classified as active by the prototype. Most of these discordant phage-bacteria couples produced a spot in the spot test, suggesting the assay may detect but not distinguish killing without replication from killing with replication. The method showed high repeatability and reproducibility. A few aberrant species specificity results highlighted the need for routine controls. Results from prospective urine samples were obtained within an average of 5 h. IMPORTANCE: The lack of reproducible user-friendly phage susceptibility testing that can timely inform clinical decisions remains a major barrier to the routine clinical use of phages. We developed a high-throughput, semi-automated prototype that delivers easy-to-interpret phage susceptibility results for four bacterial species within 5 h in a “real-life” clinical flow. However, the correlation between in vitro lytic activity and clinical outcomes still needs to be established to meet regulatory requirements for in vitro diagnostic (IVD) medical devices.

  • Open Access

    Managing of Acute Pediatric Cough in Africa: prescription of Cough Suppressants and Associated Complications

    by Benoît Mukinayi Mbiya, Denis Kalambayi Mbuyi, Steve Tshiala Kasongo, Valery Daubie

    Background: The use of antitussives is a crucial issue in pediatrics and can lead to respiratory complications that can affect the prognosis. Objectives: to determine the frequency of respiratory complications associated with the use of an-titussives in pediatrics in a remote city in the Democratic Republic of Congo. Method: This is a cross-sectional retrospective study conducted between January 1, 2017 and De-cember 2022. Patients under 12 years of age with an acute cough were eligible. The parameters studied were treatment with cough suppressants and associated respiratory complications. Results: A total of 218 children suffered from an acute cough. The average age was 11 months 10, the sex ratio (H/F) was 126/92. In 30% of cases, children were treated with cough suppressants for an average of 7 days prior to admission. Respiratory complications were observed in 11% (23/218) of cases. The majority of these complications, 61% (14 of 23), had received antitussive treatment prior to hospitalization. Respiratory complications were associated with cough medications (p-value = 0.0012, relative risk (RR) = 3.66, IC90 [1.696; 7,873]). Acute respiratory distress was reported in 87% (20/23) of cases and was associated with the use of cough suppressants (p-value = 0.0065, RR: 3.060, IC90: [1.433; 6,485]). Conclusion: The use of antitussives in pediatrics poses a risk of acute respiratory distress in a remote city that does not have sufficient human and material resources for management. Keywords: cough, cough suppressants, pediatrics, complications, Mbujimayi, Democratic Republic of Congo.

  • Open Access

    Composite lymphoma associating diffuse large B‐cell lymphoma with classical Hodgkin lymphoma

    by Maïlis Lauwers, Valéry Daubie, Hussein Farhat, Laureen Rocq, Anne‐Laure Trépant, Laura Vanoverschelde

  • Open Access

    Evaluation and Modelling of the Performance of an Automated SARS-CoV-2 Antigen Assay According to Sample Type, Target Population and Epidemic Trends

    by Nicolas Yin, Cyril Debuysschere, Valery Daubie, Marc Hildebrand, Charlotte Martin, Sonja Curac, Fanny Ponthieux, Marie-Christine Payen, Olivier Vandenberg, Marie Hallin

    The Lumipulse® G SARS-CoV-2 Ag assay performance was evaluated on prospectively collected saliva and nasopharyngeal swabs (NPS) of recently ill in- and outpatients and according to the estimated viral load. Performances were calculated using RT-PCR positive NPS from patients with symptoms ≤ 7 days and RT-PCR negative NPS as gold standard. In addition, non-selected positive NPS were analyzed to assess the performances on various viral loads. This assay yielded a sensitivity of 93.1% on NPS and 71.4% on saliva for recently ill patients. For NPS with a viral load > 103 RNA copies/mL, sensitivity was 96.4%. A model established on our daily routine showed fluctuations of the performances depending on the epidemic trends but an overall good negative predictive value. Lumipulse® G SARS-CoV-2 assay yielded good performance for an automated antigen detection assay on NPS. Using it for the detection of recently ill patients or to screen high-risk patients could be an interesting alternative to the more expensive RT-PCR.


  • Open Access

    Improvement of Sickle Cell Disease Morbimortality in Children: Experience in a Remote Area of an African Country

    by Benoît Mukinayi Mbiya, Didier Kalenda Kalombo, Yannick Nkesu Mukendi, Valery Daubie, John Kalenda Mpoyi, Parola Mukendi Biboyi, Ghislain Tumba Disashi, Béatrice Gulbis

    Background: Sickle cell disease (SCD) is a public health problem in the Democratic Republic of Congo. While reference sickle cell centers have been implemented in capital cities of African countries and have proven to be beneficial for SCD patients, they have never been set up in rural areas for families with very low sources of income. Method: A cohort of 143 children with SCD aged 10 years old (IQR (interquartile range): 6–15 years) (sex ratio male/female = 1.3) were clinically followed for 12 months without any specific intervention aside from the management of acute events, and then for 12 months with a monthly medical visit, biological follow-up, and regular prophylaxis. Results: The median age of patients at the diagnosis of SCD was 2 years (IQR: 1–5). The implementation of standardized and regular follow-ups in a new sickle cell referral center in a remote city showed an increase in the annual mean hemoglobin level from 50 to 70 g/L (p = 0.001), and a decrease in the lymphocyte count and spleen size (p < 0.001). A significant decrease (p < 0.001) in the average annual number of hospitalizations and episodes of vaso-occlusive crises, blood transfusions, infections, and acute chest syndromes were also observed. Conclusions: Creation of a sickle cell referral center and the regular follow-up of children with SCD are possible and applicable in the context of a remote city of an African country and represent simple and accessible measures that can reduce the morbimortality of children with sickle cell disease.